April 2026

PDR Drug Update 

Treating Motion Sickness in Adults

Motion sickness is a common condition that results from a conflict between visual input, proprioceptive feedback, and the vestibular apparatus of the inner ear, the primary sensory organ responsible for balance and spatial orientation. This mismatch activates neural pathways that regulate nausea and vomiting. Motion sickness can be brought on by travel, such as when on a train, plane, or car, or by activities like riding roller coasters or playing video games. Although symptoms typically resolve after motion ceases, episodes can significantly impair comfort and normal functioning.

Pharmacological management for motion sickness has traditionally included antihistamines such as dimenhydrinate and meclizine, which are available over the counter. Another option is the transdermal scopolamine patch, an established therapy often used when longer-lasting relief is needed. These medications act on pathways associated with vestibular signaling and have been used for decades for both prevention and symptom control. While effective for many patients, others experience inadequate relief or have intolerable side effects. A newly FDA-approved medication, Nereus (tradipitant), offers an additional therapeutic approach that may help address the needs of individuals with motion sickness. Its approval represents the first therapy specifically indicated for vomiting due to motion sickness.

Nereus is an NK-1 receptor antagonist that blocks the binding of substance P, interrupting signaling within nervous system pathways that regulate the vomiting reflex. The recommended dosage is 85mg or 170mg taken orally on an empty stomach approximately one hour prior to travel or anticipated motion exposure. In clinical studies, adults receiving Nereus experienced a lower incidence of vomiting during motion exposure compared with placebo. Common side effects of Nereus include fatigue, somnolence, and headache.

The availability of an NK-1 receptor antagonist expands the range of options for adults affected by motion sickness. With the introduction of a new antiemetic, alongside established therapies, clinicians now have greater flexibility in tailoring treatment to individual patient needs. Stay informed about emergent drug information, including treatment options for motion sickness, by exploring PDR by ConnectiveRx. You can also stay current by using the official PDR app, mobilePDR, which is available for free from your preferred app store.

FDA New Approvals

Bysanti

The FDA has approved Bysanti (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. Learn more about Bysanti

Desmoda

The FDA has approved Desmoda (desmopressin acetate) oral solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency, as antidiuretic replacement therapy for patients of all ages. Learn more about Desmoda

Icotyde

The FDA has approved Icotyde (icotrokinra), an interleukin-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older who weigh at least 40kg who are candidates for systemic therapy or phototherapy. Learn more about Icotyde

Loargys

The FDA has approved Loargys (pegzilarginase-nbln), an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction. Learn more about Loargys

Lynavoy

The FDA has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis. Learn more about Lynavoy

Yuviwel

The FDA has approved Yuviwel (navepegritide) as a once-weekly treatment indicated to increase linear growth in children aged 2 years and older with achondroplasia with open epiphyses. Learn more about Yuviwel

FDA New Indications

Arexvy

The FDA approved an expanded age indication for Arexvy (Respiratory Syncytial Virus vaccine, [adjuvanted]). It now includes adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV. The RSV vaccine was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50–59 at increased risk for LRTD caused by RSV. Learn more about Arexvy

Cosentyx

The FDA has approved Cosentyx (secukinumab) for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa. Learn more about Cosentyx

Dupixent

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis who have a history of sino-nasal surgery. Learn more about Dupixent

Hernexeos

The FDA has approved Hernexeos (zongertinib) tablets for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. Learn more about Hernexeos

Palynziq

The FDA has approved Palynziq (pegvaliase-pqpz) to include treatment of pediatric patients aged 12 years and older with phenylketonuria. Learn more about Palynziq

Sogroya

The FDA has approved three new indications for once-weekly Sogroya (somapacitan-beco) injection 5mg, 10mg, or 15mg. Sogroya is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, short stature born Small for Gestational Age and with no catch-up growth by age 2 years, or growth failure associated with Noonan Syndrome. Sogroya is also indicated for children aged 2.5 years and older and adults with growth hormone deficiency. Learn more about Sogroya

Sotyktu

The FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. Learn more about Sotyktu

Wellcovorin

The FDA has approved expanded use of Wellcovorin (leucovorin calcium) tablets to treat cerebral folate deficiency in patients with a confirmed variant in the folate receptor one gene. Learn more about Wellcovorin

FDA New Combinations

Braftovi Combination Regimen

The FDA has approved Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation. Learn more about Braftovi combination regimen

Tecvayli + Darzalex Faspro

The FDA has approved Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab/hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Learn more about Tecvayli + Darzalex Faspro

FDA New Dosing

Desmoda

The FDA has approved Desmoda (desmopressin acetate) oral solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency, as antidiuretic replacement therapy for patients of all ages. Learn more about Desmoda

Wegovy HD

The FDA has approved Wegovy HD (semaglutide) 7.2mg, a once-weekly injectable to reduce excess body weight and maintain weight reduction long-term. Learn more about Wegovy HD

FDA Drug Safety Communications

Carbidopa/Levodopa Products

The FDA has notified application holders for all drug products containing carbidopa/levodopa that the Agency is requiring the addition of a warning, and corresponding revisions, to the prescribing information to state that these medications, approved to treat symptoms of Parkinson’s disease, can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures. The warning directs healthcare professionals to evaluate baseline vitamin B6 levels prior to starting treatment with carbidopa/levodopa therapies and periodically while on treatment and to supplement with vitamin B6 as necessary. Learn more about the carbidopa/levodopa products drug safety communication

Labeling Updates - No updates this month